Evidence map›Paper›PMID 42285912›Full record

ArticlemAbs2026

Comparison of knockdown approaches for the generation of stable cell populations expressing afucosylated antibodies.

Maria Tsachaki, Andrew Samy, Mégane Peltret, Timothee Brunstein Laplace, Emilie Vaxelaire-Hily, Farid Mosbaoui, Anna Galea, Francesca Contarin, Lionel Duarte, Roberto Giovannini and 1 more

Abstract readComparative Study
In one paragraph

Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maria TsachakiDrug Substance Development, IGI Therapeutics SA, La Chaux-de-Fonds, Switzerland.
Andrew SamyDrug Substance Development, IGI Therapeutics SA, La Chaux-de-Fonds, Switzerland.ORCID 0000-0001-9152-1327
Mégane PeltretDrug Substance Development, IGI Therapeutics SA, La Chaux-de-Fonds, Switzerland.
Timothee Brunstein LaplaceDrug Substance Development, IGI Therapeutics SA, La Chaux-de-Fonds, Switzerland.
Emilie Vaxelaire-HilyDrug Substance Development, IGI Therapeutics SA, La Chaux-de-Fonds, Switzerland.
Farid MosbaouiDrug Substance Development, IGI Therapeutics SA, La Chaux-de-Fonds, Switzerland.
Anna GaleaDrug Substance Development, IGI Therapeutics SA, La Chaux-de-Fonds, Switzerland.
Francesca ContarinDrug Substance Development, IGI Therapeutics SA, La Chaux-de-Fonds, Switzerland.
Lionel DuarteDrug Substance Development, IGI Therapeutics SA, La Chaux-de-Fonds, Switzerland.
Roberto GiovanniniProcess Development, IGI Therapeutics SA, La Chaux-de-Fonds, Switzerland.
Martin BertschingerDrug Substance Development, IGI Therapeutics SA, La Chaux-de-Fonds, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeted silencing of cellular genes in cell lines stably expressing a secreted recombinant protein offers a flexible and convenient strategy for modulating product quality attributes. However, unlike genetic knockout of a cellular gene or the use of potent inhibitors to eliminate cellular enzyme activity, gene knockdown approaches using microRNAs (miRNA) or short hairpin RNAs (shRNA) may result in only partial reduction of enzyme activity and only partial change of the desired product quality attribute. Moreover, through saturation of the Dicer pathway, shRNA may introduce cytotoxic effects that affect product yield. In this study, we demonstrate that miRNAs are a more suitable tool than shRNAs for α1,6-fucosyltransferase (FUT8) knockdown in Chinese hamster ovary (CHO) cells, when expressed under the control of an RNA-Polymerase II promoter. In the presence of miRNAs targeted to the FUT8 mRNA, the fucosylation levels of the N-glycan linked to Asn297 (EU numbering) of a recombinant monoclonal antibody (mAb) were considerably reduced (>90% afucosylation by hydrophilic interaction liquid chromatography - high‑performance liquid chromatography; no detectable fucosylated product by intact mass spectrometry), without a relevant impact on mAb expression. By comparison, overexpression of shRNAs targeted to the FUT8 mRNA resulted in higher levels of residual fucosylation of the mAb and a larger reduction in mAb titers. miRNAs overcame a limitation of the knockdown approach with shRNAs, making this approach a valuable tool for biopharmaceutical manufacturing.

Indexed as

Antibodies, MonoclonalFucoseFucosyltransferasesGene Knockdown TechniquesAnimalsCHO CellsCricetinaeCricetulusGlycosylationHumansMicroRNAsRecombinant ProteinsRNA, Small InterferingAntibodies, MonoclonalFucoseFucosyltransferasesGlycoprotein 6-alpha-L-fucosyltransferaseMicroRNAsRecombinant ProteinsRNA, Small Interferingafucosylationantibody expressionCHO cellsKnockdown

Identifiers

PMID42285912
PMCPMC13274123

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.